Click Therapeutics vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
$50M Series D from Boehringer Ingelheim in Apr 2026. Develops prescription digital therapeutics for depression, schizophrenia, and other conditions.
About
Click Therapeutics develops FDA-regulated prescription digital therapeutics (PDT) for conditions including depression, schizophrenia, migraine, and smoking cessation. The company partners with pharma — including Boehringer Ingelheim, Otsuka, and Sanofi — to co-develop and commercialize PDTs alongside traditional pharmacologic treatments.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.